系统范围综述:利用粪便免疫化学检测残留缓冲液增强结直肠癌筛查
该范围综述检索PubMed、Scopus、Web of Science、Embase和Google Scholar至2023年10月25日,纳入使用家庭采集定量FIT并首先处理血红蛋白的18项研究,总结FIT残留缓冲液中蛋白质、DNA/RNA和微生物组生物标志物与结直肠肿瘤的关联及稳定性,为后续验证研究提供框架。
要点
- FIT残留缓冲液中多种蛋白质、DNA/RNA和微生物组标志物与结直肠肿瘤相关。
- 研究关注了生物标志物短期稳定性(临床使用)和长期稳定性(研究用途)。
- 该综述为利用FIT残留缓冲液非侵入性增强结直肠癌筛查的进一步验证研究提供框架。
核心结论
- 该范围综述总结了FIT残留缓冲液中生物标志物稳定性及其与结直肠肿瘤关联的研究框架和进展,为后续验证研究增强结直肠癌筛查提供指导。
研究设计与样本
- 系统范围综述,检索PubMed、Scopus、Web of Science、Embase和Google Scholar截至2023年10月25日的文献,检索词包括FIT、缓冲液、OC-sensor、生物标志物、微生物组、microRNA(miR)、结肠、直肠、筛查、肿瘤和早期检测。
- 纳入使用家庭采集样本、采用定量FIT并首先处理血红蛋白的研究;一位作者审阅所有文章,第二位作者完成20%全文审核以确保符合纳入标准。
- 广泛检索获得1669项研究,应用纳入标准后确定18项相关研究。
主要发现
- 多种蛋白质、DNA/RNA和微生物组生物标志物( notably 触珠蛋白、miR-16、miR-27a-3p、miR-92a、miR-148a-3p、miR-223、miR-421、let-7b-5p和Tyzzerella 4)与结直肠肿瘤相关。
- 研究强调了生物标志物用于临床的短期稳定性和用于研究目的的长期稳定性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The faecal immunochemical test (FIT) is an inexpensive and convenient modality to screen for colorectal cancer. However, its one-time sensitivity for detecting colorectal cancer and cancer precursors is limited. There is growing interest in using the non-haemoglobin contents of FIT residual buffer to enhance colonic neoplasia detection. AIM: To establish from the literature a framework to catalogue candidate biomarkers within FIT residual buffer for non-invasive colorectal cancer screening. METHODS: The search strategy evaluated PubMed, Scopus, Web of Science, Embase, and Google Scholar for publications through 25 October 2023, with search terms including FIT, buffer, OC-sensor, biomarkers, microbiome, microRNA (miR), colon, rectum, screening, neoplasm, and early detection. Studies employing home-based collection samples using quantitative FIT first processed for haemoglobin were included. One author reviewed all articles; a second author completed a 20% full-text audit to ensure adherence to eligibility criteria. RESULTS: A broad search yielded 1669 studies and application of eligibility criteria identified 18 relevant studies. Multiple protein, DNA/RNA, and microbiome biomarkers (notably haptoglobin, miR-16, miR-27a-3p, miR-92a, miR-148a-3p, miR-223, miR-421, let-7b-5p, and Tyzzerella 4) were associated with colorectal neoplasia. Furthermore, studies highlighted the short-term stability of biomarkers for clinical use and long-term stability for research purposes. CONCLUSIONS: This scoping review summarises the framework and progress of research on stability of biomarkers in FIT residual buffer and their associations with colorectal neoplasia to guide opportunities for further confirmatory studies to enhance colorectal cancer screening.
引用
- McAuliffe T, Anderson JC, Larson RJ, et al. Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening. Aliment Pharmacol Ther. 2024. PMID: 38534182. doi:10.1111/apt.17947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。